Table 3 Outcomes of patients
Outcomes | P-ALG (N = 28) | R-ATG (N = 63) | P value |
|---|---|---|---|
Time of engraftment | |||
 ANC, days (range) | 11 (10–22) | 13 (10–23) | 0.294 |
 PLT, days (range) | 12.5 (8–95) | 15 (10–83) | 0.465 |
Infection | |||
 CMV | |||
  Yes | 13 (46.4%) | 45 (71.4%) | 0.022 |
  No | 15 (53.6%) | 18 (28.6%) | |
 EBV | |||
  Yes | 1 (3.6%) | 16 (25.4%) | 0.014 |
  No | 27 (96.4%) | 47 (74.6%) | |
 IFD | |||
  Yes | 1 (3.6%) | 6 (9.5%) | 0.577 |
  No | 27 (96.4%) | 57 (90.5%) | |
 Severe bacterial infection | |||
  Yes | 5 (17.9%) | 16 (25.4%) | 0.431 |
  No | 23 (82.1%) | 47 (74.6%) | |
 Graft rejection | |||
  Yes | 0 (0%) | 6 (9.5%) | 0.218 |
  No | 28 (100%) | 57 (90.5%) | |
GVHD | |||
 aGVHD, % | 65.39 ± 9.33 | 62.71 ± 6.30 | 0.653 |
 II–IV aGVHD, % | 38.46 ± 9.54 | 35.64 ± 6.24 | 0.695 |
 III–IV aGVHD, % | 19.23 ± 7.73 | 10.53 ± 4.07 | 0.291 |
 cGVHD, % | 22.22 ± 12.25 | 22.31 ± 6.30 | 0.915 |
 Moderate-severe cGVHD, % | 5.56 ± 5.40 | 9.28 ± 4.46 | 0.993 |
 5-year OS, % | 74.83 ± 8.24 | 72.29 ± 6.26 | 0.830 |
 5-year GFFS, % | 71.05 ± 8.65 | 62.71 ± 6.22 | 0.662 |
 5-year FFS, % | 74.83 ± 8.24 | 66.09 ± 5.84 | 0.647 |
 5-year TRM, % | 25.17 ± 8.24 | 26.29 ± 6.22 | 0.708 |